ClinicalTrials.gg
RecruitingNCT06497790Updated Jul 12, 2024

BJH-SDS Validation of the German Translation

An observational study in Dysphagia and Stroke, Acute, sponsored by University of Giessen. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-07-12.

Sponsored by University of Giessen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
570
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Deglutition Disorders with a site in Germany — 6 open to participants now, 6 under way, none of them phase 3. Deglutition Disorders · Germany.

Started
2024
the only one that year
Observational
9 of 27
4 open now
Registered
24th of 27
by date
Lead sponsor
4 of 27
University of Giessen

Among the 27 studies in Deglutition Disorders with a site in Germany, this one is the only one that started in 2024, is one of 9 observational ones, and was the 24th registered.

Deglutition Disorders

875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

Browse Deglutition Disorders studies →

Open to participants now

6 of the 27 studies in Deglutition Disorders with a site in Germany are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 137 Deglutition Disorders studies recruiting now, 75 (55%) set no upper age limit and 26 (19%) stop at 75 or younger; 15 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Deglutition Disorders with a site in Germany, or all of them as a file.
02

Study summary

The first object of the study is the validation of a translation of the Barnes-Jewish Hospital Stroke Dysphagia Screen with determination of sensitivity, specificity, interrater reliability (especially between different professional groups) and criterion validity.

If the German translation proves to be suitable, it will also be validated on general neurological patients, i.e. patients on a neurological ward without a stroke.

Read the detailed description

Stroke is now the second most common cause of death worldwide. Dysphagia is described as a direct consequence of cerebral infarction in at least 50% of stroke patients in the acute phase [2]. It often leads to aspiration pneumonia, which is the most important secondary complication in stroke unit. Within one year after a stroke, around 20% of dysphagia patients die as a result of aspiration pneumonia . In addition, dysphagia causes numerous other secondary complications (malnutrition, exsiccosis) and associated high costs for the healthcare system.

Numerous screening procedures have been developed in recent years. These are mostly based on a swallowing test with water after testing various input requirements. There are also multi-consistency tests that include liquids as well as pulpy and solid consistencies. The sensitivity of the tests is usually at least 85% with moderate specificity, which is due to the inability to detect silent aspiration by non-instrumental diagnostics. In addition, the implementation of the screening procedures is usually only evaluated by the professional group of speech therapists.

One of these screening procedures is the Barnes-Jewish-Hospital Stroke Dysphagia Screen (BJH-SDS). In our opinion, this test is very well suited as a screening procedure, as it has good sensitivity (94%) and specificity (64%), is validated for all professional groups and takes little time. In brief, it includes an assessment of sufficient consciousness (Glasgow Coma Scale over 13 points), a check for facial paresis, soft palate paresis and tongue paresis followed by a water swallow test with 90 ml of water if the previous points are assessed as normal. The water swallow test checks for signs of aspiration (throat clearing, coughing or a change in voice quality) However, the BJH-SDS is not yet available in German. The aim of this research project is therefore to translate the BJH-SDS into German (BJH-SDS-G) and validate it as the gold standard using flexible endoscopic swallowing examination (FEES) and then use it routinely in our clinics. This will be followed by validation in general neurological patients (without stroke) so that the BJH-SDS can also be used reliably in this patient population.

03

Conditions studied

  • Dysphagia
  • Stroke, Acute

Keywords

  • Stroke
  • Dysphagia
  • Swallowing disorders
  • FEES
  • Swallow screening
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

  • Acute ischemic stroke Patients
  • General patient popluation
  • Non-neurologic ICU patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All stroke patients in the neurology department of the Lahn-Dill Clinic in Wetzlar and the stroke unit of the Bürgerhospital in Friedberg and the neurologic ICU of the University Hospital in Giessen are to be screened with the BJH-SDS-G after appropriate information has been provided.

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria are a lack of , to an FEES examination, a history of stroke, pre-existing dysphagia or a disease that may be associated with dysphagia (e.g. ENT tumors, Parkinson's disease, neuromuscular diseases).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
570 participants (estimated)
Patient registry
No

Groups and cohorts

  • Acute stroke patients

    All patients of the participating clinics who have a suspected diagnosis of stroke

    Diagnostic Test: BJH-SDS Screenint Test · Diagnostic Test: Flexible Endoscopic Evaluation of Swallowing

  • Non-neurologic ICU patients

    All patients of the participating clinics who are being treated in intensive care due to a non-neurological disease

    Diagnostic Test: BJH-SDS Screenint Test · Diagnostic Test: Flexible Endoscopic Evaluation of Swallowing

  • Non-neurologic patientes

    All patients of the participating clinics who are being treated due to a non-neurological disease

    Diagnostic Test: BJH-SDS Screenint Test · Diagnostic Test: Flexible Endoscopic Evaluation of Swallowing

Interventions

  • Diagnostic testBJH-SDS Screenint Test

    The test includes the assessment of a sufficient level of consciousness (Glasgow Coma Scale over 13 points), a check for facial paresis, soft palate paresis and tongue paresis followed by a water swallow test with 90 ml of water if the previous points are assessed as normal. The water swallow test checks for signs of aspiration (throat clearing, coughing or a change in voice quality)

  • Diagnostic testFlexible Endoscopic Evaluation of Swallowing

    The FEES evaluates anatomical changes, functional disorders of the visible structures (e.g. recurrent paresis), saliva management, penetration and aspiration of food boluses in order to draw conclusions about the underlying pathomechanism of dysphagia. It is an established standard diagnostic procedure for stroke patients and, in addition to the diagnosis of dysphagia, also enables pathomechanism-guided therapy by speech therapists

    Also known as: FEES

06

What researchers measure

Primary outcomes

  1. Penetration-Aspiration Score

    Penetration-Aspiration-Score, minimum value 1, maximum value 8; higher scores mean worse outcome

    Time frame: Immediately after the intervention

  2. Barthel-Index

    Barthel-Index; minimal value 0, maximum value 100; lower values mean worse outcome

    Time frame: Immediately before the intervention

  3. MRS

    Modified Rankin Scale; minimal value 0, maximum value 6; higher values mean worse score

    Time frame: Immediately before the intervention

07

Study locations

1 of 1 sites recruiting
  • University Hospital Giessen and Marburg, Campus Giessen
    Giesen, Hessen 35392, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2026, 24 months after the start.

Of 116 non-industry observational studies under Deglutition Disorders, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 52. This study's planned 24 months is close to that.

Counting every sponsor, half of 119 studies reached it within 25 months; a quarter within 11 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2024
First posted
Jul 12, 2024
StartActual
Apr 15, 2024
Primary completionEst.
Apr 15, 2026
CompletionEst.
May 1, 2026
Last update
Jul 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06497790
Lead sponsor
University of Giessen
Responsible party
Sponsor
First posted
Jul 12, 2024
Start date
Apr 15, 2024
Primary completion
Apr 15, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Jul 12, 2024

Study contacts

Tobias Braun, PD MD
Contact
tobias.braun@neuro.med.uni-giessen.de
+49 6441793517
Tobias Braun, PD MD
study director · University of Giessen
Samra Hamzic, Dr.
principal investigator · University of Giessen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion